crb-701
Generic: SYS6002·Code: SYS6002
crb-701: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | Phase 1 |
FDA Decisions
FDA_MeetingFDA granted Fast Track designation to CRB-701 for recurrent or metastatic head and neck squamous cell carcinoma previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy.(CRBP)
Frequently asked questions
Who is developing crb-701?
crb-701 is being developed by Corbus Pharmaceuticals Holdings, Inc..
What is crb-701's latest FDA decision?
The most recent tracked FDA decision for crb-701 is FDA_Meeting for FDA granted Fast Track designation to CRB-701 for recurrent or metastatic head and neck squamous cell carcinoma previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy., dated September 16, 2025.
Get deeper analysis on crb-701
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis